Matthew Procopio, MD
Family Medicine · Camillus, NYNPI 1679992135
Payments from drug & device makers
Across 180 payments — averaging $16.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$622
- GSK$428
- Pfizer$336
- Astellas Pharma US Inc$190
- Novo Nordisk$154
- Amgen$120
- plus $1K from 32 others
What the payments were for
- Food & beverage$3,027100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 37 | $622 |
| GSK | 30 | $428 |
| Pfizer | 27 | $336 |
| Astellas Pharma US Inc | 9 | $190 |
| Novo Nordisk | 9 | $154 |
| Amgen | 6 | $120 |
| Incyte Corporation | 4 | $111 |
| Lilly USA, LLC | 6 | $107 |
| Irhythm Technologies, Inc. | 2 | $83 |
| Merck | 4 | $71 |
| Kyowa Kirin, Inc. | 2 | $58 |
| Amarin Pharma, Inc. | 4 | $54 |
| Boehringer Ingelheim | 3 | $52 |
| AstraZeneca | 3 | $51 |
| Mannkind Corporation | 2 | $45 |
| Sumitomo Pharma America, Inc. | 2 | $44 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $40 |
| Johnson & Johnson | 3 | $38 |
| Seqirus USA Inc | 2 | $37 |
| Exact Sciences | 1 | $31 |
| Collegium Pharmaceutical, Inc. | 2 | $31 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $30 |
| Upsher-smith Laboratories LLC | 2 | $30 |
| Inspire Medical Systems, Inc. | 1 | $28 |
| Abbott | 1 | $23 |
| Sanofi Pasteur Inc. | 1 | $22 |
| Corcept Therapeutics | 1 | $20 |
| Ferring Pharmaceuticals Inc. | 1 | $20 |
| Genentech USA, Inc. | 1 | $19 |
| Bayer | 1 | $18 |
| Otsuka America Pharmaceutical, Inc. | 1 | $17 |
| Sanofi-aventis U.S. LLC | 1 | $16 |
| Phadia US Inc. | 1 | $16 |
| Fidia Pharma USA Inc. | 1 | $15 |
| IBSA Pharma Inc. | 1 | $14 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $13 |
| Arbor Pharmaceuticals, Inc. | 1 | $13 |
| Mylan Specialty L.p. | 1 | $12 |
How this compares
$3,027 in reported general payments places this provider in the 80th percentile of 4,321 family medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 55 | $86,747 |
| JardianceEmpagliflozin | 51 | $78,139 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 57 | $67,551 |
| OzempicSemaglutide | 40 | $56,797 |
| RybelsusSemaglutide | 28 | $54,806 |
| XareltoRivaroxaban | 27 | $41,593 |
| Breo ElliptaFluticasone/Vilanterol | 30 | $26,084 |
| TrulicityDulaglutide | 20 | $24,819 |
| JanuviaSitagliptin Phosphate | 22 | $24,371 |
| MounjaroTirzepatide | 13 | $15,991 |
| Spiriva HandihalerTiotropium Bromide | 11 | $15,597 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 20 | $12,035 |
| Atorvastatin Calcium | 788 | $7,843 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 12 | $7,207 |
| AbrysvoRsv Vacc, Pref A And Pref B/Pf | 20 | $6,258 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Shingrix | $428 | $111,838135 claims |
| Novo NordiskOzempic, Rybelsus | $154 | $111,60368 claims |
| PfizerEliquis, Abrysvo | $336 | $93,00575 claims |
| Boehringer IngelheimJardiance | $52 | $78,13951 claims |
| Johnson & JohnsonXarelto | $38 | $41,59327 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $107 | $40,81033 claims |
| MerckJanuvia | $71 | $24,37122 claims |
| AbbVieSynthroid | $622 | $3,07643 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,321 family medicine providers in New York.
Other family medicine in Camillus
- Matthew DavisRochester$76.6M
- Frank EderBinghamton$46.2M
- Suchet PatelEndwell$23.3M
- James WildGowanda$2.2M
- Michael FedericoEndwell$1.4M
- Donald BrautigamWestfield$1.3M
- Kimberly DesantisEndwell$1.1M
- Michael TugetmanHartsdale$1M
- Richard RuhOrchard Park$769K
- Eric LorraineEndwell$740K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.